Telaprevir: An NS3/4A protease inhibitor for the treatment of chronic hepatitis C;Telaprevir: Un inhibidor de proteasa NS3·4A para el tratamiento de hepatitis C crónica

Annals of Pharmacotherapy

Volumn 45, Issue 5, 2011, Pages 639-649

  Smith, Lisa S ^a   Nelson, Michael ^b   Naik, Sagar ^a   Woten, Joanna ^a  

^a WINGATE UNIVERSITY   (United States)

^b REGIS UNIVERSITY   (United States)

Author keywords

Chronic hepatitis C; NS3 4A; Telaprevir; VX 950

Indexed keywords

PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PLACEBO; RIBAVIRIN; TELAPREVIR;

ANEMIA; ARTICLE; DEPRESSION; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; LOADING DRUG DOSE; MACULOPAPULAR RASH; MEDLINE; MONOTHERAPY; NAUSEA; NONHUMAN; PATIENT COUNSELING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; VIRUS RESISTANCE;

ANIMALS; HEPATITIS C, CHRONIC; HUMANS; OLIGOPEPTIDES; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRAL NONSTRUCTURAL PROTEINS;

EID: 79957597421     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P430     Document Type: Article

References (52)

1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clinics Liver Dis 2005;9:383-398, vi.
2. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
3. Deuffic-Burban S, Poynard T, Sulkowski MS, Wong JB. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepatitis 2007;14:107-115.
4. McHutchison JG, Bacon BR. Chronic hepatitis C: anage wave of disease burden. Am J Managed Care 2005;11(10 suppl):S286-295.
5. Perni RB, Almquist SJ, Byrn RA, et al. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006;50:899-909.
6. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology (Baltimore) 2009;49:1335-1374.
7. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358: 958-65.
8. Joyce MA, Tyrrell DL. The cell biology of hepatitis C virus. Microbes Infect 2010;12:263-271.
9. Gentile I, Carleo MA, Borgia F, Castaldo G, Borgia G. The efficacy and safety of telaprevir-a new protease inhibitor-against hepatitis C virus. Expert Opin Investig Drugs 2010;19:151-159.
10. Steinkuhler C, Urbani A, Tomei L, et al. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J Virol 1996;70:6694-6700.
11. Wolk B, Sansonno D, Krausslich HG, et al. Subcellular localization, stability, and trans-cleavage competence of the hepatitis C virus NS3-NS4A complex expressed in tetracycline-regulated cell lines. J Virol 2000;74: 2293-2304.
12. De Francesco R, Carfi A. Advances in the development of new therapeutic agents targeting the NS3- 4A serine protease or the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. Adv Drug Deliv Rev 2007;59:1242-1262.
13. Gentile I, Viola C, Borgia F, Castaldo G, Borgia G. Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2009;16:1115-1121.
14. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-945.
15. Thomson JA, Perni RB. Hepatitis C virus NS3- 4A protease inhibitors: countering viral subversion in vitro and showing promise in the clinic. Curr Opin Drug Discov Devel 2006;9:606-617.
16. Flores MV, Strawbridge J, Ciaramella G, Corbau R. HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism. Biochim Biophys Acta 2009;1794:1441-1448.
17. Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3- 4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells. Antimicrob Agents Chemother 2006;50:1813-1822.
18. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004;85:3173-3188.
19. Welsch C, Domingues FS, Susser S, et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3- 4A protease of the hepatitis C virus. Genome Biol 2008;9:R16.
20. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-462.
21. Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin. J Med Virol 2010;82:575-582.
22. McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008;52:1604-1612.
23. Bartels DJ, Zhou Y, Zhang EZ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis 2008;198:800-807.
24. Cubero M, Esteban JI, Otero T, et al. Naturally occurring NS3-proteaseinhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 2008;370:237-245.
25. Kuntzen T, Timm J, Berical A, et al. Naturally occurring dminant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology (Baltimore) 2008;48:1769-7178.
26. Foster GR, Hezode C, Bronowicki JP, et al. Activity of telaprevir alone or in combination with peginterferon alfa-2a and ribavirin in treatmentnaive genotype 2 and 3 hepatitis-C patients: interim results of study C209. J Hepatol 2009;50(suppl 1):S22.
27. Benhamou Y, Moussalli J, Ratzui V, et al. Results of a proof of concept study (C210) of telaprevir monotherapy and in combination with peginterferon alfa-2a and ribavirin in treatment-naive genotype 4 HCV patients. J Hepatol 2009;50(suppl 1):S6.
28. McCown MF, Rajyaguru S, Kular S, Cammack N, Najera I. GT-1a or GT- 1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob Agents Chemother 2009;53:2129-2132.
29. Forestier N, Reesink HW, Weegink CJ, et al. Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology (Baltimore) 2007;46:640-648.
30. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon- alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology (Baltimore) 2007;46:631-639.
31. Sarrazin C, Kieffer TL, Bartels D, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132:1767-1777.
32. Reesink HW, Zeuzem S, Weegink CJ, et al. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006;131:997-1002.
33. Kempf DJ, Klein C, Chen HJ, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by codosing with ritonavir. Antivir Chem Chemother 2007;18:163-167.
34. Jacobson IM, McHutchison JG, Dusheiko GM, et al. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatmentnaïve patients: Final results of phase 3 ADVANCE study (abstract 211). American Association for the Study of Liver Diseases 2010.
35. Sherman KE. Telaprevir in combination with peginterferon alfa2a and ribavirin for 24 or 48 weeks in treatment-naïve genotype 1 HCV patients who achieved an extended rapid viral response: final results of phase 3 ILLUMINATE study (abstract LB-2). American Association for the Study of Liver Diseases 2010.
36. Vertex Pharmaceuticals. 65% of People whose prior treatment for hepatitis C was unsuccessful achieved SVR (viral cure) with telaprevir-based therapy in Phase 3 REALIZE study. http://investors.vrtx.com/releasedetail.cfm?releaseid=505239 (accessed 2011 Jan 5).
37. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008;49:163-169.
38. Suzuki F, Akuta N, Suzuki Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks. Hepatol Res 2009;39:1056-1063.
39. Suzuki F, Suzuki Y, Akuta N, et al. Sustained virological response in a patient with chronic hepatitis C treated by monotherapy with the NS3- 4A protease inhibitor telaprevir. J Clin Virol 2010;47:76-8.
40. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
41. Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360:1839-1850.
42. McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010;362:1292-1303.
43. Vertex Pharmaceuticals. New data from Phase 3 studies showed superior SVR (viral cure) rates achieved with telaprevir-based combination therapy in people with hepatitis C, regardless of race or stage of liver disease. http://investors.vrtx.com/releasedetail.cfm?releaseid=525062 (accessed 2011 Jan 5).
44. Decision Resources. Hepatitis C: reimbursement and uptake of novel antivirals among payers and prescribers. http://www.decisionresourcesgateway.com/index.aspx?StoryID=0&ReportI D=1736&Lang=en&MainPage=renderTOC (accessed 2010 Oct 10).
45. Fowell AJ, Nash KL. Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010;27:512-522.
46. Vertex Pharmaceuticals. Initiation of Phase 3b clinical trial to evaluate twice-daily (BID) dosing of telaprevir. http://investors.vrtx.com/releasedetail.cfm?releaseid=522615 (accessed 2011 Jan 5).
47. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990;150:1881-1884.
48. Schmidt S, Sheikzadeh S, Beil B, Patten M, Stettin J. Acceptance of telemonitoring to enhance medication compliance in patients with chronic heart failure. Telemed J E Health 2008;14:426-433.
49. Clinical Trials.gov. Safety and efficacy of telaprevir in combination with peginterferon alfa-2a and ribavirin in subjects co-infected with hepatitis C virus (HCV) and HIV. http://www.clinicaltrial.gov/ct2/show/NCT00983853?term=telaprevir+AND+HI V&rank=1 (accessed 2011 Jan 5).
50. Seden K, Back D, Khoo S. New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals. J Antimicrob Chemother 2010;65:1079-1085.
51. Vertex Pharmaceuticals. Vertex provides update to ongoing Phase 2 study evaluating combinations of telaprevir and VX-222 for the treatment of hepatitis C. http://investors.vrtx.com/releasedetail.cfm?ReleaseID=538347 (accessed 2011 Jan 5).
52. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-3401.